search
Back to results

Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)

Primary Purpose

Idiopathic Intracranial Hypotension, Venous Sinus Stenosis

Status
Recruiting
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Stent Implantation
Acetazolamide-based medical therapy
Weight loss
Sponsored by
Beijing Tiantan Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Idiopathic Intracranial Hypotension focused on measuring Idiopathic intracranial hypertension, Venous sinus stenosis, Stenting, Medical therapy, Randomized controlled trial

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subject Eligibility Criteria Diagnosis of IIH by modified Dandy criteria for more than 2 months Lumbar puncture opening pressure ≥250 mmH₂O within 6 weeks before enrollment Normal cerebrospinal fluid (CSF) composition Neuroimaging showing normal brain parenchyma without hydrocephalus, mass, or any structural lesion and no evidence of meningeal enhancement on CT or MRI Localized venous sinus stenosis (VSS) with stenotic degree ≥ 50% on DSA, and pressure gradient across stenosis ≥ 8 mmHg Patients or their relatives signed written informed consent Ophthalmic Eligibility Criteria: At least one eye had the presence of papilledema At least one eye of visual field loss: PMD ranging from - 2dB and below; decreased visual function on automated perimetry was reproducible with a false-positive rate of no more than 15% Visual acuity above 20 / 200 (≥ 39 letters) Exclusion Criteria: Subject Exclusion Criteria Previous surgery for IIH, including optic nerve sheath fenestration (ONSF), CSF shunting, decompressive craniectomy or venous sinus stenting Visual loss due to other etiologies (eg, retinal drusen, retinal and optic neuropathy, cataracts, etc) Other condition requiring the use of diuretics, steroids or other drugs to reduce intracranial pressure DSA showed diffused venous sinus stenosis, cortical or deep vein stenosis A history of severe thyroid disease and iodine allergy Pregnant or lactating women Severe cardiopulmonary, liver or kidney failure Known hereditary or acquired haemorrhagic diathesis Known hereditary or acquired thrombophilia Platelet counts or coagulation abnormality Major surgery or severe trauma or any traumatic brain injury within the previous 14 days A history of cerebral hemorrhage, arteriovenous malformation, intracranial aneurysm or tumor Other life threatening illness (eg, advanced cancer) likely to lead to death within a few months; the physical, psychological and social status of patients may affect follow-up (eg, drug addiction, advanced malignant disease, no telephone, no family, etc); cannot tolerate general anesthesia Increased intracranial pressure due to other secondary factors Ophthalmic Exclusion Criteria: Current intraocular pressure > 28mmHg or previous intraocular pressure > 30mmHg Refractive error spherical power greater than -6.0D or +6.0D and astigmatism greater than 3.0D, except for the following cases: Myopia of - 6.0D to - 8.0D with the following: 1)There was no myopia related disease that can lead to decreased vision under the eyeground microscope (eg, scleral staphyloma, retinal thinning at the posterior pole, and moderate to severe disc tilt); 2) The patient wore contact lenses of appropriate degree for all visual field examinations. Hyperopia of +6.0D to +8.0D with the following: 1) The presence of a well characterized peri optic disc edematous halo, as opposed to crowded small optic discs or other features of decreased visual acuity associated with hyperopic changes, was at the discretion of the site investigator or reading center leader (or his designee); 2) The patient wore contact lenses of appropriate degree for all visual field examinations. Examination visible or past medical history known to have large optic disc drusen (persistent optic disc edema can present with small optic disc drusen, as low numbers are acceptable for inclusion and to be determined by the investigator to be unrelated to vision loss)

Sites / Locations

  • Beijing Tiantan HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Stent Implantation

Medical Therapy

Arm Description

The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure.

The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily. In addition, the weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.

Outcomes

Primary Outcome Measures

Perimetric Mean Deviation (PMD)
The change in perimetric mean deviation (PMD) from baseline to 6 month in the eye with the most severe visual loss at baseline.

Secondary Outcome Measures

Cerebrospinal Fluid (CSF) Opening Pressure
The change in intracranial pressure measured by lumbar puncture opening pressure from baseline to 6 months.
Papilledema Grade: Frisén grade(0-5 scores,and higher scores mean worse outcome)
The change in papilledema measured by Frisén grade from baseline to 6 months
Retinal Nerve Fiber Layer Thickness
The change in thickness of retinal nerve fiber layer measured by optical coherence tomography (OCT) from baseline to 6 months.
Total Retinal Thickness
The change in thickness of total retina measured by optical coherence tomography (OCT) from baseline to 6 months.
Visual Acuity: National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25, minimum and maximum values: 0-100 points, higher scores mean a better visual function)
The change in vision measured by National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) from baseline to 6 months.
Visual Acuity: 10-item neuro-ophthalmic supplement to the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) (minimum and maximum values: 0-100 points, higher scores mean a better visual function)
The change in vision measured by 10-item neuro-ophthalmic supplement to the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)from baseline to 6 months.
Headache: Headache Impact Test-6 (HIT-6, minimum and maximum values: 36-78 points, higher scores mean greater headache severity)
The change in headache measured by Headache Impact Test-6 (HIT-6) questionnaire from baseline to 6 months.
Pulsatile tinnitus: Tinnitus Handicap Inventory (THI, minimum and maximum values: 0-100 points, higher scores mean more serious tinnitus disability)
The change in pulsatile tinnitus from baseline to 6 months;pulsatile tinnitus was assessed using the Tinnitus Handicap Inventory (THI), which is a self-report measure that can be used in a busy clinical practice to quantify the impact of tinnitus on daily living.

Full Information

First Posted
December 25, 2022
Last Updated
February 14, 2023
Sponsor
Beijing Tiantan Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05707442
Brief Title
Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)
Official Title
Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 31, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Tiantan Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to assess the efficacy of stent implantation versus medical therapy on idiopathic intracranial hypertension with venous sinus stenosis.
Detailed Description
The SIMPLE is a multicentered, prospective, randomized, open-label, blinded end-point clinical trial. A total of 74 patients with idiopathic intracranial hypertension (IIH) and venous sinus stenosis (VSS) for more than 2 months will be enrolled. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups (stenting or medical therapy) after offering informed content.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Idiopathic Intracranial Hypotension, Venous Sinus Stenosis
Keywords
Idiopathic intracranial hypertension, Venous sinus stenosis, Stenting, Medical therapy, Randomized controlled trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
74 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Stent Implantation
Arm Type
Experimental
Arm Description
The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure.
Arm Title
Medical Therapy
Arm Type
Active Comparator
Arm Description
The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily. In addition, the weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
Intervention Type
Procedure
Intervention Name(s)
Stent Implantation
Intervention Description
Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
Intervention Type
Drug
Intervention Name(s)
Acetazolamide-based medical therapy
Intervention Description
The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
Intervention Type
Behavioral
Intervention Name(s)
Weight loss
Intervention Description
The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
Primary Outcome Measure Information:
Title
Perimetric Mean Deviation (PMD)
Description
The change in perimetric mean deviation (PMD) from baseline to 6 month in the eye with the most severe visual loss at baseline.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Cerebrospinal Fluid (CSF) Opening Pressure
Description
The change in intracranial pressure measured by lumbar puncture opening pressure from baseline to 6 months.
Time Frame
6 months
Title
Papilledema Grade: Frisén grade(0-5 scores,and higher scores mean worse outcome)
Description
The change in papilledema measured by Frisén grade from baseline to 6 months
Time Frame
6 months
Title
Retinal Nerve Fiber Layer Thickness
Description
The change in thickness of retinal nerve fiber layer measured by optical coherence tomography (OCT) from baseline to 6 months.
Time Frame
6 months
Title
Total Retinal Thickness
Description
The change in thickness of total retina measured by optical coherence tomography (OCT) from baseline to 6 months.
Time Frame
6 months
Title
Visual Acuity: National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25, minimum and maximum values: 0-100 points, higher scores mean a better visual function)
Description
The change in vision measured by National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) from baseline to 6 months.
Time Frame
6 months
Title
Visual Acuity: 10-item neuro-ophthalmic supplement to the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) (minimum and maximum values: 0-100 points, higher scores mean a better visual function)
Description
The change in vision measured by 10-item neuro-ophthalmic supplement to the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)from baseline to 6 months.
Time Frame
6 months
Title
Headache: Headache Impact Test-6 (HIT-6, minimum and maximum values: 36-78 points, higher scores mean greater headache severity)
Description
The change in headache measured by Headache Impact Test-6 (HIT-6) questionnaire from baseline to 6 months.
Time Frame
6 months
Title
Pulsatile tinnitus: Tinnitus Handicap Inventory (THI, minimum and maximum values: 0-100 points, higher scores mean more serious tinnitus disability)
Description
The change in pulsatile tinnitus from baseline to 6 months;pulsatile tinnitus was assessed using the Tinnitus Handicap Inventory (THI), which is a self-report measure that can be used in a busy clinical practice to quantify the impact of tinnitus on daily living.
Time Frame
6 months
Other Pre-specified Outcome Measures:
Title
Functional health status and quality of life:EuroQol five dimensions questionnaire (EQ-5D,0-100,higher scores mean a better outcome)
Description
The change in functional health status and quality of life measured by EuroQol five dimensions questionnaire (EQ-5D) from baseline to 6 months
Time Frame
6 months
Title
Cost-effectiveness analysis (mean costs per patient)
Description
The indicator of cost-effectiveness analysis refers to the mean costs per patient.
Time Frame
6 months
Title
Cost-effectiveness analysis (quality-adjusted life years)
Description
The indicator of cost-effectiveness analysis refers to the quality-adjusted life years.
Time Frame
6 months
Title
Cost-effectiveness analysis (the cost saving per extra patient with a good outcome)
Description
The indicator of cost-effectiveness analysis refers to the cost saving per extra patient with a good outcome.
Time Frame
6 months
Title
Cost-effectiveness analysis (the cost saving per additional quality-adjusted life year)
Description
The indicator of cost-effectiveness analysis refers to the cost saving per additional quality-adjusted life year.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject Eligibility Criteria Diagnosis of IIH by modified Dandy criteria for more than 2 months Lumbar puncture opening pressure ≥250 mmH₂O within 6 weeks before enrollment Normal cerebrospinal fluid (CSF) composition Neuroimaging showing normal brain parenchyma without hydrocephalus, mass, or any structural lesion and no evidence of meningeal enhancement on CT or MRI Localized venous sinus stenosis (VSS) with stenotic degree ≥ 50% on DSA, and pressure gradient across stenosis ≥ 8 mmHg Patients or their relatives signed written informed consent Ophthalmic Eligibility Criteria: At least one eye had the presence of papilledema At least one eye of visual field loss: PMD ranging from - 2dB and below; decreased visual function on automated perimetry was reproducible with a false-positive rate of no more than 15% Visual acuity above 20 / 200 (≥ 39 letters) Exclusion Criteria: Subject Exclusion Criteria Previous surgery for IIH, including optic nerve sheath fenestration (ONSF), CSF shunting, decompressive craniectomy or venous sinus stenting Visual loss due to other etiologies (eg, retinal drusen, retinal and optic neuropathy, cataracts, etc) Other condition requiring the use of diuretics, steroids or other drugs to reduce intracranial pressure DSA showed diffused venous sinus stenosis, cortical or deep vein stenosis A history of severe thyroid disease and iodine allergy Pregnant or lactating women Severe cardiopulmonary, liver or kidney failure Known hereditary or acquired haemorrhagic diathesis Known hereditary or acquired thrombophilia Platelet counts or coagulation abnormality Major surgery or severe trauma or any traumatic brain injury within the previous 14 days A history of cerebral hemorrhage, arteriovenous malformation, intracranial aneurysm or tumor Other life threatening illness (eg, advanced cancer) likely to lead to death within a few months; the physical, psychological and social status of patients may affect follow-up (eg, drug addiction, advanced malignant disease, no telephone, no family, etc); cannot tolerate general anesthesia Increased intracranial pressure due to other secondary factors Ophthalmic Exclusion Criteria: Current intraocular pressure > 28mmHg or previous intraocular pressure > 30mmHg Refractive error spherical power greater than -6.0D or +6.0D and astigmatism greater than 3.0D, except for the following cases: Myopia of - 6.0D to - 8.0D with the following: 1)There was no myopia related disease that can lead to decreased vision under the eyeground microscope (eg, scleral staphyloma, retinal thinning at the posterior pole, and moderate to severe disc tilt); 2) The patient wore contact lenses of appropriate degree for all visual field examinations. Hyperopia of +6.0D to +8.0D with the following: 1) The presence of a well characterized peri optic disc edematous halo, as opposed to crowded small optic discs or other features of decreased visual acuity associated with hyperopic changes, was at the discretion of the site investigator or reading center leader (or his designee); 2) The patient wore contact lenses of appropriate degree for all visual field examinations. Examination visible or past medical history known to have large optic disc drusen (persistent optic disc edema can present with small optic disc drusen, as low numbers are acceptable for inclusion and to be determined by the investigator to be unrelated to vision loss)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xu Tong, MD
Phone
+8617611338800
Email
dongri0514@sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dapeng Mo, MD
Organizational Affiliation
Beijing Tiantan Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Zhongrong Miao, MD
Organizational Affiliation
Beijing Tiantan Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beijing Tiantan Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100010
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dapeng Mo, MD
Phone
+8613691419036‬
Email
modapeng1971@163.com

12. IPD Sharing Statement

Learn more about this trial

Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)

We'll reach out to this number within 24 hrs